EmailPrintShare

News

Quotient Sciences acquires Pharmaterials

15 November 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Quotient Sciences regarding its acquisition of Pharmaterials, a UK-based Contract Development and Manufacturing Organisation. Quotient Sciences (“Quotient”), the early phase drug development services provider, announced that it has acquired Pharmaterials, a contract development and manufacturing…Read more
EmailPrintShare


Envision Pharma Group acquires Touch Creative Design Limited

15 November 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company Envision Pharma Group regarding its acquisition of Touch Creative Design Limited, a UK-based Pharma/Healthcare focused agency with multi-industry experience. To underpin their commitment to clients to provide pioneering scientific multichannel medical communication solutions alongside their purpose…Read more
EmailPrintShare


Quotient Clinical acquires QS Pharma from Charles River Laboratories International, Inc.

14 February 2017 London, UK – GHO Capital, the European specialist investor in healthcare, is pleased to share today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of QS Pharma, increasing its US presence and adding high potency molecule capabilities to its existing operations. Addition of contract development and manufacturing organisation increases scale…Read more
EmailPrintShare


Quotient Clinical Acquires SeaView Research

6 February 2017 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Quotient Clinical regarding its acquisition of SeaView Research, expanding its existing operational footprint to the US. Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired SeaView Research…Read more
EmailPrintShare


DNA Diagnostics Center Acquires IDENTIGENE LLC from Sorenson Genomics LLC

2 December 2016 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company DNA Diagnostics Center ® (“DDC”) regarding the acquisition of the assets of IDENTIGENE®, LLC, a wholly owned subsidiary of Sorenson Genomics, LLC. As a significant consumer brand in parentage testing, distributed at over 20,000 retail…Read more
EmailPrintShare


GHO Capital closes €660 million private equity fund

25 November 2016 London, UK – GHO Capital, the European specialist investor in healthcare, today announces the successful final close for GHO Capital Fund I LP, a €660 million private equity fund which has been raised to seize the highly attractive and underpenetrated investment opportunity in European healthcare. GHO Capital Fund I LP (“the Fund”)…Read more
EmailPrintShare


Caprion Biosciences Acquires the Immune Monitoring Laboratory from ImmuneHealth

13 September 2016 London, UK – GHO Capital, the European specialist investor in healthcare, acknowledges today’s announcement from its portfolio company Caprion Biosciences, Inc. (“Caprion” or “the Company”) regarding the acquisition of the assets of the immune monitoring laboratory of ImmuneHealth, ASBL. Located in Gosselies, Belgium, the ImmuneHealth laboratory will provide a fully operational immune…Read more
EmailPrintShare


GHO Capital announces acquisition of Caprion Biosciences

20 July 2016 London, UK – GHO Capital, the European specialist investor in healthcare, today announces the acquisition of Caprion Biosciences, Inc. (“Caprion” or “the Company”), the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion is a specialist laboratory services company which provides testing services to pharmaceutical and…Read more
EmailPrintShare


GHO Capital & Ardian team with Envision leadership to acquire the Envision Pharma Group from the Halifax Group

6 July 2016 London, UK – GHO Capital, the European specialist investor in healthcare, in collaboration with Ardian, the independent private investment company, has partnered with the Envision Pharma Group’s (“Envision”) leadership team to acquire Envision, a leading Medical Affairs-focused scientific communications and technology solutions provider, from the Halifax Group. The management team and employees,…Read more
EmailPrintShare


GHO Capital announces two acquisitions to create pan-European ophthalmic specialty pharmaceutical company

5 July 2016 London, UK – GHO Capital, the European specialist investor in healthcare, has entered into an agreement to acquire the European commercial operations of Nicox S.A. (“Nicox”) (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and to acquire the entire issued share capital of Visufarma Spa (“Visufarma”), a private Italian ophthalmic company. The…Read more
EmailPrintShare